- AU$5.34m
- AU$5.18m
- AU$0.41m
Annual cashflow statement for Inhalerx, fiscal year end - December 31st, AUD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Changes in Working Capital | 0.01 | 0.015 | 0.016 | 0.443 | 0.767 |
Other Operating Cash Flow | |||||
Cash from Operating Activities | -1.05 | -1.15 | -1.85 | -1.96 | -0.369 |
Capital Expenditures | -0.004 | -0.025 | -0 | 0 | — |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | — | — | — | — | 0 |
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.004 | -0.025 | -0 | 0 | 0 |
Financing Cash Flow Items | -0.037 | -0.013 | -0.024 | -0.002 | -0.006 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 2.37 | 2.26 | 1.18 | 0.544 | -0.152 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 1.29 | 1.08 | -0.67 | -1.42 | -0.521 |